Payers still will want to limit access to these drugs given the massive number of patients that could be eligible for treatment.
Will The Introduction Of A Third Potent Cholesterol Lowering Drug Expand or Shrink The Market?
Payers still will want to limit access to these drugs given the massive number of patients that could be eligible for treatment.